PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY COMBINED WITH SYSTEM CHEMOTHERAPY – A NEW APPROACH TO TREATMENT OF GASTRIC CANCER PATIENTS WITH PERITONAL CARCINOMATOSIS

The aim of the study was to analyze the immediate and long-term outcomes of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal carcinomatosis (PC).
Material and methods. The treatment protocol included diagnostic laparoscopy with PCI score assessment and peritoneal biopsy and 4 courses of systemic chemotherapy with XELOX or FOLFOX followed by PIPAC with cisplatin and doxorubicin at 6–8 week intervals. Between the PIPAC cycles patients received systemic chemotherapy according to previous regimen. Each PIPAC procedure included laparoscopy, evaluation of Peritoneal Carcinomatosis Index (PCI) and peritoneal biopsies.
Results. 102 (80.3 %) patients had primary gastric cancer with PC and 25 (19.7 %) had peritoneal recurrence of gastric cancer. PCI<10 points was found in 60 (47.2%) patients, PCI 10–18 in 33 (26 %) patients and PCI>18 in 34 (26.7 %) patients. Diffuse type of cancer was diagnosed in 114 patients (89.7 %), intestinal type in 6 (4.7 %) patients and the mixed type in 7 (5.5 %) patients. 127 patients underwent 310 PIPAC procedures. No severe complications and were observed. Pathological response (PRGC score) was evaluated in 72 patients. Partial pathological response (PRGS 2) was achieved in 40 (55.6 %) cases and complete pathological response (PRGS 1) – in 10 (13.9 %). Survival was evaluated in 63 % (n=80) patients who received more than one PIPAC. The median survival was 16.0 months and one year survival rate was 77.9 %.
Conclusion. A new approach to the treatment of gastric cancer with PC combining systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy is a simple and save method allowing improvement of survival of patients with peritoneal dissemination of gastric cancer.

gastric cancer, peritoneal carcinomatosis, pressurized intraperitoneal aerosol chemotherapy

1. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017. Moscow: 2016: 411. (in Russian).

2. Kaprin A.D., Sobolev D.D., Khomiakov V.M., Bolotina L.V., Riabov A.B., Khoronenko V.É., Shemetova M.M., Kramskaia L.V., Kolobaev I.V., Ivanov A.V., Utkina A.B. Experience with hyperthermic intraoperative intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer (Cyt+). P.A. Herzen Journal of Oncology. 2015; (1): 67–70. (in Russian).

3. Nashimoto A., Akazawa K., Isobe Y., Miyashiro I., Katai H., Kodera Y., Tsujitani S., Seto Y., Furukawa H., Oda I., Ono H., Tanabe S., Kaminishi M. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013 Jan; 16(1): 1–27. doi: 10.1007/s10120-012-0163-4.

4. Stepanov I.V., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; (5): 45–53. (in Russian).

5. Roviello F., Marrelli D., de Manzoni G., Morgagni P., Di Leo A., Saragoni L., De Stefano A.; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003 Sep; 90(9): 1113–9. doi: 10.1002/bjs.4164.

6. Thomassen I., van Gestel Y.R., van Ramshorst B., Luyer M.D., Bosscha K., Nienhuijs S.W., Lemmens V.E., de Hingh I.H. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014 Feb 1; 134(3): 622–8. doi: 10.1002/ijc.28373.

7. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., Fontaumard E., Brachet A., Caillot J.L., Faure J.L., Porcheron J., Peix J.L., François Y., Vignal J., Gilly F.N. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000 Jan 15; 88(2): 358–63. doi: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o.

8. Kuramoto M., Shimada S., Ikeshima S., Matsuo A., Yagi Y., Matsuda M., Yonemura Y., Baba H. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009 Aug; 250(2): 242–6. doi: 10.1097/SLA.0b013e3181b0c80e.

9. Besova N.S., Bolotina L.V., Kalinin A.E., Kononets P.V., Malikhova O.A., Protsenko S.A. Practical recommendations for the treatment of gastric cancer. Malignant tumors. Practical recommendations of RUSSCO. 2019 9 (3s2): 308–323. (in Russian).

10. Rivera F., Vega-Villegas M.E., López-Brea M.F. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007 Jun; 33(4): 315–24. doi: 10.1016/j.ctrv.2007.01.004.

11. Mori T., Fujiwara Y., Sugita Y., Azama T., Ishii T., Taniguchi K., Yamazaki K., Takiguchi S., Yasuda T., Yano M., Monden M. Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol. 2004 Jan; 11(1): 14–20. doi: 10.1007/BF02524340.

12. Elias D., Gilly F., Boutitie F., Quenet F., Bereder J.M., Mansvelt B., Lorimier G., Dubè P., Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1; 28(1): 63–8. doi: 10.1200/JCO.2009.23.9285.

13. Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., Pujade- Lauraine E., Ray-Coquard I., Sehouli J., Harter P., du Bois A.; AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012 Oct; 23(10): 2605–12. doi: 10.1093/annonc/mds203.

14. Kaprin A.D., Khomyakov V.M., Sobolev D.D., Bolotina L.V., Ryabov A.B., Khoronenko V.E., Soboleva M.M., Kramskaya L.V. Our experience of hyperthermic intraperitoneal chemotherapy for patients with advanced gastric cancer. Research and Practical Medicine Journal. 2015; 2(4): 17–27. (in Russian). doi: 10.17709/2409-2231-2015-4.

15. Gill R.S., Al-Adra D.P., Nagendran J., Campbell S., Shi X., Haase E., Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011 Nov 1; 104(6): 6928. doi: 10.1002/jso.22017.

16. Chia C.S., You B., Decullier E., Vaudoyer D., Lorimier G., Abboud K., Bereder J.M., Arvieux C., Boschetti G., Glehen O.; BIG RENAPE Group. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 2016 Jun; 23(6): 1971–9. doi: 10.1245/s10434-015-5081-3.

17. Solass W., Kerb R., Mürdter T., Giger-Pabst U., Strumberg D., Tempfer C., Zieren J., Schwab M., Reymond M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014 Feb; 21(2): 553–9. doi: 10.1245/s10434-013-3213-1.

18. Reymond M.A., Hu B., Garcia A., Reck T., Köckerling F., Hess J., Morel P. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000 Jan; 14(1): 515. doi: 10.1007/s004649900010.

19. Solaß W., Hetzel A., Nadiradze G., Sagynaliev E., Reymond M.A. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012 Jul; 26(7): 1849–55. doi: 10.1007/s00464-012-2148-0.

20. Eveno C., Haidara A., Ali I., Pimpie C., Mirshahi M., Pocard M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum. 2017 Jun 1; 2(2): 103–109. doi: 10.1515/pp-2017-0015.

21. Nadiradze G., Giger-Pabst U., Zieren J., Strumberg D., Solass W., Reymond M.A. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. J Gastrointest Surg. 2016 Feb; 20(2): 367–73. doi: 10.1007/s11605-015-2995-9.

22. Kaprin A.D., Khomyakov V.M., Ryabov A.B., Bolotina L.V., Ivanov A.V., Utkina A.B., Volchenko N.N. Pressurized intraperitoneal aerosol chemotherapy (PIAC) in combination with systemic chemotherapy for stomach cancer patients with peritoneal dissemination. Pharmateca. 2016; 330(17): 59–65. (in Russian).

23. Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82: 359–74. doi: 10.1007/978-1-4613-1247-5_23.

24. Alberto M., Brandl A., Garg P.K., Gül-Klein S., Dahlmann M., Stein U., Rau B. Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview. Clin Exp Metastasis. 2019 Feb; 36(1): 1–14. doi: 10.1007/s10585-019-09955-4.